“BioChaperone® 222, the new excipient enabling the ultra-rapid BioChaperone® Lispro formulation, is completely absorbed and rapidly excreted after subcutaneous injection” (Poster 816), presented by Dr. Olivier Soula, 54th Annual Meeting of the European Association for the Study of Diabetes, 1-5 October 2018, Berlin (Germany)